In-hospital thromboprophylaxis variation and the risk of venous thromboembolism after lung cancer surgery: a nationwide cohort study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
In-hospital thromboprophylaxis variation and the risk of venous thromboembolism after lung cancer surgery : a nationwide cohort study. / Christensen, Thomas Decker; Ording, Anne Gulbech; Skjøth, Flemming; Mørkved, Amalie Lambert; Jakobsen, Erik; Meldgaard, Peter; Petersen, Rene Horsleben; Søgaard, Mette.
In: Interdisciplinary CardioVascular and Thoracic Surgery , Vol. 38, No. 5, ivae081, 2024.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - In-hospital thromboprophylaxis variation and the risk of venous thromboembolism after lung cancer surgery
T2 - a nationwide cohort study
AU - Christensen, Thomas Decker
AU - Ording, Anne Gulbech
AU - Skjøth, Flemming
AU - Mørkved, Amalie Lambert
AU - Jakobsen, Erik
AU - Meldgaard, Peter
AU - Petersen, Rene Horsleben
AU - Søgaard, Mette
N1 - Publisher Copyright: © The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
PY - 2024
Y1 - 2024
N2 - OBJECTIVES: Venous thromboembolic event (VTE) is a severe complication in patients with lung cancer undergoing thoracic surgery. Nevertheless, because of insufficient evidence, there are no clear guidelines, and VTE prophylaxis practices vary widely. This nationwide cohort study was a comparative study investigating VTE risk in surgical departments that routinely administered in-hospital thromboprophylaxis with low-molecular-weight heparin compared to those that did not. METHODS: We identified all patients with non-small-cell lung cancer (NSCLC) who underwent surgery in Denmark during 2010–2021. Thoracic surgery was exclusively performed in the 4 university hospitals. Three hospitals implemented in-hospital thromboprophylaxis as standard care since 2000, while the fourth adopted this practice in September 2016. VTE events were assessed at 6-month follow-up according to hospital and study period, using an inverse probability of treatment weighting approach. RESULTS: We identified 9615 patients. During 6-month follow-up, a total of 190 VTE events were observed, resulting in a weighted rate of 4.5 events per 100 person-years and an absolute risk of 2.2%. There was no clear trend according to hospital site or use of in-hospital thromboprophylaxis with a 2.2% risk in the hospital not using thromboprophylaxis compared to 1.7–3.1% in those that did. CONCLUSIONS: Use of in-hospital thromboprophylaxis did not affect the risk of VTE after surgery for NSCLC, suggesting that relying solely on in-hospital thromboprophylaxis may be insufficient to mitigate VTE risk in these patients. Further research is warranted to investigate the potential benefits of extended thromboprophylaxis in reducing VTE risk in selected NSCLC surgical patients.
AB - OBJECTIVES: Venous thromboembolic event (VTE) is a severe complication in patients with lung cancer undergoing thoracic surgery. Nevertheless, because of insufficient evidence, there are no clear guidelines, and VTE prophylaxis practices vary widely. This nationwide cohort study was a comparative study investigating VTE risk in surgical departments that routinely administered in-hospital thromboprophylaxis with low-molecular-weight heparin compared to those that did not. METHODS: We identified all patients with non-small-cell lung cancer (NSCLC) who underwent surgery in Denmark during 2010–2021. Thoracic surgery was exclusively performed in the 4 university hospitals. Three hospitals implemented in-hospital thromboprophylaxis as standard care since 2000, while the fourth adopted this practice in September 2016. VTE events were assessed at 6-month follow-up according to hospital and study period, using an inverse probability of treatment weighting approach. RESULTS: We identified 9615 patients. During 6-month follow-up, a total of 190 VTE events were observed, resulting in a weighted rate of 4.5 events per 100 person-years and an absolute risk of 2.2%. There was no clear trend according to hospital site or use of in-hospital thromboprophylaxis with a 2.2% risk in the hospital not using thromboprophylaxis compared to 1.7–3.1% in those that did. CONCLUSIONS: Use of in-hospital thromboprophylaxis did not affect the risk of VTE after surgery for NSCLC, suggesting that relying solely on in-hospital thromboprophylaxis may be insufficient to mitigate VTE risk in these patients. Further research is warranted to investigate the potential benefits of extended thromboprophylaxis in reducing VTE risk in selected NSCLC surgical patients.
KW - Epidemiology
KW - Non-small-cell lung cancer
KW - Surgery
KW - Thromboprophylaxis
KW - Venous thromboembolism
U2 - 10.1093/icvts/ivae081
DO - 10.1093/icvts/ivae081
M3 - Journal article
C2 - 38702829
AN - SCOPUS:85193269281
VL - 38
JO - Interdisciplinary CardioVascular and Thoracic Surgery
JF - Interdisciplinary CardioVascular and Thoracic Surgery
SN - 2753-670X
IS - 5
M1 - ivae081
ER -
ID: 392986125